Initial Testing (Stage 1) of M6620 (formerly VX-970), a Novel ATR Inhibitor, alone and combined with Cisplatin and Melphalan, by the Pediatric Preclinical Testing Program

BACKGROUND: M6620 is a novel inhibitor of the DNA damage repair enzyme ATR, and has potentiated the activity of cisplatin and irinotecan in NSCLC and colon cancer xenografts, respectively. PROCEDURES: M6620 was tested in vitro at concentrations ranging from 1.0 nM to 10.0 μM and at 75 nM in combinat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Kurmasheva, Raushan T., Kurmashev, Dias, Reynolds, C. Patrick, Kang, Min, Wu, Jianwrong, Houghton, Peter J., Smith, Malcolm A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876726/
https://ncbi.nlm.nih.gov/pubmed/28921800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26825
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky